Hexosylceramide

What is Hexosylceramide?

Hexosylceramide is a ceramide metabolite and a simple glycosphingolipid comprising of a ceramide backbone linked to glucose or galactose (i.e., cerebrosides). The ceramide backbone contains a long-chain base linked to a fatty acid with double bonds. Ceramide serves as the common precursor for complex sphingolipids like hexosylceramide, and its synthesis initiates at the cytosolic leaflet of the endoplasmic reticulum.

In general, glycosphingolipids like hexosylceramide play a critical role in maintaining plasma membranes in mammals and are expressed throughout vertebrate cells and fluids. Within the plasma membrane, glycosphingolipids are organized into clusters known as “lipid rafts”¹. Glycosphingolipid metabolism is exceptionally heterogeneous, with hexosylceramide representing one of the hundreds possible glycan-ceramide links².

Beyond being one of the structural components of cell membranes, glycosphingolipids have been demonstrated to play a pivotal role in regulating cell membrane function and other biological processes. These molecules are expressed in the outer leaflet of cell membranes and since their glycans face the external milieu, glycosphingolipids support cell signaling functions both outside and within the cell1.

Mutations in sphingolipids and glycosphingolipids genes, including hexosylceramide, are rare and thus have devastating effects3. Alterations in glycosphingolipid levels and plasma glycerolipids have been implicated in various diseases, including metabolic disorders, liver health, cancer, and neurological diseases.

Hexosylceramide and lipid metabolism

Metabolic disorders like obesity and type-2 diabetes are associated with the accumulation of harmful lipid intermediates. Understanding the metabolic and molecular bases of hexosylceramide’s role in metabolic health is crucial for identifying potential biomarkers. Recent research has demonstrated that changes in hexosylceramide and other plasma lipids can be utilized as biomarkers for metabolic diseases^4,5.

For instance, researchers investigating the metabolic health of obese cattle found decreased insulin receptor expression associated with increased concentrations of hexosylceramide in adipose tissue⁶. These findings suggest that modifications in hexosylceramide levels contribute to the insulin resistance often seen in obesity and type-2 diabetes.

However, these data are inconsistent across mammalian species. In a large-scale human lipidomics study, profiling revealed a negative correlation between hexosylceramide levels, BMI, and insulin resistance⁷. Similarly, others have demonstrated an inverse relationship between hexosylceramide levels and markers of metabolic dysfunction. In contrast, this report also found a positive correlation between vascular damage associated biomarkers and hexosylceramide levels⁸. These findings were statistically significant, highlighting the complex interactions between glycosphingolipids and metabolic health.

To emphasize this complexity, rodent models of type-2 diabetes exhibit increased muscle hexosylceramide levels, whereas type-1 diabetic rodents show decreased hexosylceramide⁹. Both groups exhibit impaired glucose metabolism, leading researchers to hypothesize that differences in diet regimens in animal models may contribute to these distinctions in hexosylceramide levels across disease states¹⁰.

Hexosylceramide and chronic hepatitis

Impaired lipid metabolism has been linked to hepatic dysfunction in liver cirrhosis, and recent research suggests that hexosylceramide and other glycosphingolipids could serve as potential biomarkers for assessing liver health.

Hexosylceramide levels have also been shown to play a role in chronic hepatitis C infections, making them potential biomarkers for the disease.

For example, fatty liver is intimately linked with obesity and lipidomic analyses have revealed significant alterations in lipid and fatty acid metabolism in mouse models of obesity. Besides significant accumulation of lipids in the liver, this study showed that while there were no significant changes in many sphingolipids, ceramides and hexosylceramide levels are reduced¹¹.

Other studies have shown that hexosylceramide is closely associated with cholesterol levels in liver cirrhosis. In a cohort of liver cirrhosis patients, one report found a negative correlation between hexosylceramide and extent of liver damage, paralleling the association between cholesterol and liver damage. Taken together, these results suggest that both hexosylceramide and cholesterol levels are promising biomarkers for liver cirrhosis¹².

To further understand the potential of hexosylceramide as a biomarker for liver disease progression, a group of researchers focused on understanding the regulation of plasma concentrations of this metabolite. Their findings revealed that ATP-binding cassette family A protein 1 (ABCA1) is important for the modulation of plasma hexosylceramide¹³. They further demonstrated that ATP-binding cassette transporter family C protein 10 (ABCC10) participates in hexosylceramide synthesis and efflux. Indeed, ABCC10 was shown to be necessary for modulating hexosylceramide levels – ABCC10 deficient mice exhibit significantly lower hepatic hexosylceramide levels¹⁴.

Hexosylceramide and oncology

Recent research has dedicated significant efforts to understanding the molecular mechanisms underlying dysregulated lipid homeostasis, an established hallmark of cancer. Sphingolipids and glycosphingolipids are included among the pivotal regulators in cancer cell growth, proliferation, survival, migration, and drug resistance.

Hexosylceramide is also involved in signal transduction processes, which are crucial for cancer cell growth and survival.

In one report, researchers performed lipidomic profiling of exomes from colorectal cancer cells¹⁵. Their findings revealed elevations in several lipids, including hexosylceramide, in cancer patients and nonmetastatic cells. Conversely, the same lipid species were decreased in nonmetastatic cells, suggesting that changes in lipid concentrations over time may provide important insight towards understanding cancer initiation and progression. Similarly, lipidomic profiling in mouse models of ovarian cancer showed dynamic lipid alterations, with an increase in hexosylceramide levels during later stages¹⁶.

Another important role for hexosylceramide and other sphingolipids in cancer biology is the regulation of apoptosis. One in vitro study revealed an accumulation of several lipids, including hexosylceramide, in response to staurosporine-induced apoptosis specifically in cancer cell lines¹⁷.

Other studies have demonstrated that alterations in hexosylceramide and other sphingolipids promote cancer cell survival and drug resistance. For instance, in a report examining estrogen therapy resistant breast cancer (ET-resistant breast cancer) patients, tamoxifen-resistant cells exhibit decreased levels of ceramide and hexosylceramide¹⁸. Interestingly, these researchers further demonstrated that perturbation of sphingolipid pathways with CERK inhibitors (a key enzyme in sphingolipid metabolism) induced programmed cell death. These data suggest that maintaining low levels of ceramide and hexosylceramide is vital for cancer cell survival.

Hexosylceramide and multiple sclerosis

Within the central nervous system, galactosylceramide accounts for 99% of hexosylceramides¹⁹, constituting 20-25% of myelin lipids²⁰. Myelin, the protective sheath encircling neuronal axons, is vital for effective neurotransmission. Impairments in lipid metabolism and myelin integrity are common features in numerous neurodegenerative diseases, positioning sphingolipids as potential biomarkers for conditions like multiple sclerosis and Alzheimer’s Disease.

A hallmark of multiple sclerosis is demyelination and axonal loss. In one report, knockout of galactosylceramide related genes in mice results in severe perturbation of myelin membranes and decreases nerve conduction²¹. One study utilizing post-mortem human brain tissue of subjects with multiple sclerosis revealed distinct sphingolipid patterns²². Notably, tissues with inactive chronic multiple sclerosis lesions exhibit reduced levels of certain ceramide species, while hexosylceramide levels are elevated. Conversely, active lesions are marked by heightened levels of major ceramide subspecies. Collectively, these findings substantiate the role of sphingolipid patterns as a promising biomarker for monitoring multiple sclerosis progression.

In multiple sclerosis, levels of palmitic acid (16:0)-containing HexCer (HexCer16:0) have been correlated with the Expanded Disability Status Scale, suggesting its potential as a marker of disease progression.

Alterations in sphingolipid levels have also been linked to Alzheimer’s disease. One study utilizing GWAS and metabolomics identified an association between a Alzheimer’s disease SNP in ABCA7 with lactosylceramide and further demonstrated that increased levels of lactosylceramide is associated with increased risk for Alzheimer’s disease²³. Additionally, ABCA7 knockout mice show altered levels of hexosylceramide that was associated with microglia activation. These findings suggest that targeting sphingolipid pathways may be a strong candidate for therapeutic opportunities in Alzheimer’s disease.

Hexosylceramide in research

As of June 2024, there are nearly 49,000 citations for sphingolipid, over 40,000 citations for glycosphingolipid, and 229 citations for hexosylceramide in research publications (excluding books and documents) on Pubmed. Many studies utilize human plasma samples to investigate the role of hexosylceramide in various diseases. The vast number of publications in recent years linking sphingolipids to a variety of physiological functions and disease (many of which discussed here) suggests that any research program seeking to better understand metabolic and liver health, cancer biology, and neurological diseases may benefit from quantitative measurement of glycosphingolipids like hexosylceramide. Considering the widespread effects of sphingolipids on the human body, preclinical research may also benefit from hexosylceramide quantification for a comprehensive understanding of biomarkers, diagnosis, disease monitoring, and treatment.

Research has also explored the role of intestinal epithelial cells in the absorption and transport of hexosylceramide, particularly in relation to lipid metabolism.

References

1. Degroote S, Wolthoorn J, and van Meer G. The cell biology of glycosphingolipids. Semin Cell Dev Biol. 2004;(15):375-387.
2. D’Angelo G, Capasso S, Sticco L, et al. Glycosphingolipids: synthesis and functions. FEBS J. 2013;(280):6338-6353.
3. Zhou H, Wu Z, Wang Y, et al. Rare Diseases in Glycosphingolipid Metabolism. Adv Exp Med Biol. 2022;(1372):189-213.
4. Summers, SA. Could Ceramides Become the New Cholesterol? Cell Metab. 2018;(27):276-280.
5. Iqbal J, Walsh MT, Hammad SM, et al. Sphingolipids and Lipoproteins in Health and Metabolic Disorders. Trends Endocrinol Metab. 2017;(28):506-518.
6. Kenez A, Bassler SC, Jorge-Smeding E, et al. Ceramide metabolism associated with chronic dietary nutrient surplus and diminished insulin sensitivity in the liver, muscle, and adipose tissue of cattle. Front Physiol. 2022;(13):958837.
7. Chew WS, Torta F, Ji S, et al. Large-scale lipidomics identifies associations between plasma sphingolipids and T2DM incidence. JCI Insight. 2019;(5).
8. Berkowitz L, Salazar C, Ryff CD, et al. Serum sphingolipid profiling as a novel biomarker for metabolic syndrome characterization. Front Cardiovasc Med. 2022;(9):1092331.
9. Bozic J, Markotic A, Cikes-Culic V, et al. Ganglioside GM3 content in skeletal muscles is increased in type 2 but decreased in type 1 diabetes rat models: Implications of glycosphingolipid metabolism in pathophysiology of diabetes. J Diabetes. 2018;(10):130-139.
10. Obanda DN, Yu Y, Wang ZQ, et al. Modulation of sphingolipid metabolism with calorie restriction enhances insulin action in skeletal muscle. J Nutr Biochem. 2015;(26):687-695.
11. Eisinger K, Krautbauer S, Hebel T, et al. Lipidomic analysis of the liver from high-fat diet induced obese mice identifies changes in multiple lipid classes. Exp Mol Pathol. 2014;(97):37-43.
12. Krautbauer S, Wiest R, Liebisch G, et al. Associations of systemic sphingolipids with measures of hepatic function in liver cirrhosis are related to cholesterol. Prostaglandins Other Lipid Mediat. 2017;(131):25-32.
13. Iqbal J, Walsh MT, Hammad SM, et al. Microsomal Triglyceride Transfer Protein Transfers and Determines Plasma Concentrations of Ceramide and Sphingomyelin but Not Glycosylceramide. J Biol Chem. 2015;(290):25863-25875.
14. Iqbal J, Walsh MT, and Hussain MM. ATP-Binding Cassette Transporter Family C Protein 10 Participates in the Synthesis and Efflux of Hexosylceramides in Liver Cells. Nutrients. 2022;(14).
15. Elmallah MIY, Ortega-Deballon P, Hermite L, et al. Lipidomic profiling of exosomes from colorectal cancer cells and patients reveals potential biomarkers. Mol Oncol. 2022;(16):2710-2718.
16. Bifarin OO, Sah S, Gaul DA, et al. Machine Learning Reveals Lipidome Remodeling Dynamics in a Mouse Model of Ovarian Cancer. J Proteome Res 2023;(22):2092-2108.
17. del Solar V, Lizardo DY, Li N, et al. Differential Regulation of Specific Sphingolipids in Colon Cancer Cells during Staurosporine-Induced Apoptosis. Chem Biol. 2015;(22):1662-1670.
18. Pal P, Millner A, Semina SE, et al. Endocrine Therapy-Resistant Breast Cancer Cells Are More Sensitive to Ceramide Kinase Inhibition and Elevated Ceramide Levels Than Therapy-Sensitive Breast Cancer Cells. Cancers (Basel) 2022;(14).
19. Vanier MT and Svennerholm L. Chemical pathology of Krabbe’s disease. III. Ceramide-hexosides and gangliosides of brain. Acta Paediatr Scand. 1975;(64):641-648.
20. O’Brien JS and Sampson EL. Lipid composition of the normal human brain: gray matter, white matter, and myelin. J Lipid Res. 1965;(6):537-544.
21. Bosio A, Binczek E, and Stoffel W. Functional breakdown of the lipid bilayer of the myelin membrane in central and peripheral nervous system by disrupted galactocerebroside synthesis. Proc Natl Acad Sci U S A. 1996;(93):13280-13285.
22. Podbielska M, Szulc ZM, Ariga T, et al. Distinctive sphingolipid patterns in chronic multiple sclerosis lesions. J Lipid Res. 2020;(61):1464-1479.
23. Dehghan A, Pinto RC, Karaman I, et al. Metabolome-wide association study on ABCA7 indicates a role of ceramide metabolism in Alzheimer’s disease. Proc Natl Acad Sci U S A. 2022;(119):e2206083119.